Accepting New Patients
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials. Strata Oncology is initiating the Strata Trial (STR-001-001) with the primary goal of understanding the proportion of subjects available for clinical trials and approved targeted therapies in advanced cancer while assessing the feasibility of using a large-scale NGS screening program to match subjects for eligibility assessments in clinical trials and/or for approved targeted therapies. The Strata Trial does not require additional procedures but rather uses surplus, or leftover tumor specimens for molecular profiling.
- Subjects must be ≥ 18 years of age.
- Subjects must have histologically documented solid tumors or lymphoma.
- Specific criteria for individual tumor types are as follows:
- Subjects with glioblastoma.
- Subjects with pancreatic cancer are eligible at any stage of disease.
- Subjects with rare tumors (i.e. cancer started in an unusual place in the body, it is unusual type and requires special treatment) are eligible at stages II-IV
- Subjects with other tumor types must have recurrent, relapsed, refractory, metastatic or advanced stages III or IV cancer.
- Subjects must have an adequate formalin-fixed paraffin-embedded tumor specimen for genomic sequencing.